- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Vesnarinone - ...
MedChemExpress - Model Vesnarinone - 81840-15-5
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research[1][2][3][4].MCE products for research use only. We do not sell to patients.
Vesnarinone
MCE China:Vesnarinone
Brand:MedChemExpress (MCE)
Cat. No.HY-15297
CAS:81840-15-5
Synonyms:OPC-8212
Purity:98.58%
Storage:Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Shipping:Room temperature in continental US; may vary elsewhere.
Description:Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.
In Vitro:Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner[3]. Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis[3]. Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly[3].
In Vivo:Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo[4].
Hot selling product:SM-164 | S63845 | Biotin-azide | Neocarzinostatin | Indocyanine green | Celecoxib | BX795 | Cholesterol | Subasumstat | Rucaparib
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. A Matsumori, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994 Mar;89(3):955-8. [Content Brief]
[2]. E Cavusoglu, et al. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail. 1995 Jun;1(3):249-57. [Content Brief]
[3]. K Yoneda, et al. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett. 1998 Nov 13;133(1):35-45. [Content Brief]
[4]. Iain Gardner, et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem Res Toxicol. 2005 Sep;18(9):1384-94. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。